Latest articles from Medical Marketing and Media Channel

Christopher Boerner was promoted to lead commercial at BMS, and Laura Hamill joined Gilead from Amgen to head up its commercial operations.

https://www.mmm-online.com/changes-at-the-top-of-commercial-units-for-gilead-and-bms/article/791998/

Gilead appoints new commercial lead; U.K. bans online ad for contraception app; Pfizer petitions the FDA to clarify biosimilar communications.

https://www.mmm-online.com/five-things-for-pharma-marketers-to-know-wednesday-august-29-2018/article/791985/

Amarin's Vascepa trial is set to read out results by the end of September.

https://www.mmm-online.com/after-failure-of-generic-fish-oil-trial-some-caution-against-read-across-to-vascepa-study/article/791882/

Some of the advertising industry's top analysts say Mark Read looks the best choice to be WPP's chief executive and the board would need to find a "spectacular" alternative.

https://www.mmm-online.com/if-wpps-next-ceo-isnt-mark-read-its-got-to-be-a-spectacular-choice-analysts-say/article/791869/

Gilead's CAR-T cell therapy ruled too expensive in the U.K.; Experts mixed on impact of drug price hike freezes; Women turn to wearables for fertility tracking

https://www.mmm-online.com/five-things-for-pharma-marketers-to-know-tuesday-august-28-2018/article/791648/

Some of the world's most powerful pharmaceutical companies backed down on planned price increases following a new transparency law in California and social media hectoring from President Donald T...

https://www.mmm-online.com/experts-split-on-impact-of-drug-price-hike-freezes/article/791537/

Pfizer's drug tafamidis reduces risk of death; Lilly Diabetes pulls its sponsorship of Daly's car; FDA investigates electronic cigarette maker Juul.

https://www.mmm-online.com/five-things-for-pharma-marketers-to-know-monday-august-27-2018/article/791336/

Chase Design Group's John Tanner shares what he thinks brands can do to spice things up when it comes to marketing around marijuana.

https://www.mmm-online.com/the-highs-and-lows-of-cannabis-branding/article/791334/

As more medications are approved, pharma companies are being pushed farther afield into a land of bizarre — but hopefully still memorable and vaguely meaningful — drug names.

https://www.mmm-online.com/a-peek-into-the-sometimes-bizarre-land-of-pharma-brand-naming/article/790160/

White House proposes rule for drug prices in DTC ads; FDA to study impact of side-effects warnings in drug ads; FDA approves Shire's potential blockbuster HAE treatment.

https://www.mmm-online.com/five-things-for-pharma-marketers-to-know-friday-august-24-2018/article/790985/

The companies plan to make the most of favorable market access conditions for the at-home colon cancer screening test.

https://www.mmm-online.com/behind-the-exact-sciences-pfizer-cologuard-co-promotion-deal/article/790982/

Biosimilars have only been in the market for three years, but they have struggled to compete with their branded equivalents.

https://www.mmm-online.com/pfizer-lawsuit-could-clear-path-for-biosimilars/article/790686/

Latest articles from Medical Marketing and Media Channel

https://www.mmm-online.com/read-the-august-2018-digital-ediiton/article/790685/

Trump's conflicting policies on PBMs confuse the industry; Pfizer strikes deal to co-promote Cologuard; Tech company develops microchip for dementia patients.

https://www.mmm-online.com/five-things-for-pharma-marketers-to-know-thursday-august-23-2018/article/790668/

FDA extends EpiPen expiration dates; GE Ventures senior managing director departs; Facebook launches MRI research project.

https://www.mmm-online.com/five-things-for-pharma-marketers-to-know-wednesday-august-21-2018/article/790311/